Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Stomach Neoplasms 1Melanoma 1Lethal Congenital Contracture Syndrome 2 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 662pembrolizumab 612Magnetic Resonance Spectroscopy 565Carboplatin 451Cisplatin 400Cyclophosphamide 399Biopsy 385Nivolumab 329Paclitaxel 324Gemcitabine 317Radiotherapy 302Bevacizumab 250Dexamethasone 223fludarabine 217Docetaxel 203durvalumab 196Oxaliplatin 189venetoclax 188atezolizumab 188Fluorouracil 178Rituximab 177Pemetrexed 174Capecitabine 172Radiation 171Doxorubicin 168Radiosurgery 161Ipilimumab 149Etoposide 142Leucovorin 141Lenalidomide 140

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paroxetine × 90 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡